# Kura Oncology, Inc.: overview KURA · Nasdaq · CIK 1422143 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/kura.md) · [Financials](/companies/kura/financials.md) · [Filings](/companies/kura/filings.md) · [Insiders](/companies/kura/insiders.md) Latest reported revenue: [$20.9m](/filings/0001193125-26-346884.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-346884). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [14.1](/filings/0001193125-26-219481.md) | [15.3](/filings/0001193125-26-346884.md) | [20.8](/filings/0001193125-25-263589.md) | [17.3 d](/filings/0001193125-26-092567.md) | [18.3](/filings/0001193125-26-219481.md) | [20.9](/filings/0001193125-26-346884.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(458.6%)](/filings/0001193125-26-219481.md) | [(475.3%)](/filings/0001193125-26-346884.md) | [(385.5%)](/filings/0001193125-25-263589.md) | [(497.6%) d](/filings/0001193125-26-092567.md) | [(431.5%)](/filings/0001193125-26-219481.md) | [(349.8%)](/filings/0001193125-26-346884.md) | | Net margin | % | not reported | not reported | [(407.1%)](/filings/0001193125-26-346884.md) | [(432.5%)](/filings/0001193125-26-346884.md) | [(357.2%)](/filings/0001193125-25-263589.md) | [(467.2%) d](/filings/0001193125-26-092567.md) | [(401.5%)](/filings/0001193125-26-346884.md) | [(327.3%)](/filings/0001193125-26-346884.md) | | Diluted EPS | $ per share | [(0.63)](/filings/0001193125-25-263589.md) | not reported | [(0.66)](/filings/0001193125-26-219481.md) | [(0.75)](/filings/0001193125-26-346884.md) | [(0.85)](/filings/0001193125-25-263589.md) | not reported | [(0.83)](/filings/0001193125-26-219481.md) | [(0.77)](/filings/0001193125-26-346884.md) | | Free cash flow | $m | [(43.4) d](/filings/0001193125-25-263589.md) | [269 d](/filings/0001193125-26-092567.md) | [(72.2)](/filings/0001193125-26-219481.md) | [(30.2) d](/filings/0001193125-26-346884.md) | [(83.2) d](/filings/0001193125-25-263589.md) | [115 d](/filings/0001193125-26-092567.md) | [(86.0)](/filings/0001193125-26-219481.md) | [(63.2) d](/filings/0001193125-26-346884.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001193125-26-092567.md) | [53.9](/filings/0001193125-26-092567.md) | [67.5](/filings/0001193125-26-092567.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(358.5%)](/filings/0001193125-26-092567.md) | [(449.9%)](/filings/0001193125-26-092567.md) | | Net margin | % | not reported | not reported | not reported | [(322.9%)](/filings/0001193125-26-092567.md) | [(412.9%)](/filings/0001193125-26-092567.md) | | Diluted EPS | $ per share | [(1.97)](/filings/0000950170-24-021094.md) | [(2.03)](/filings/0000950170-25-029975.md) | [(2.08)](/filings/0001193125-26-092567.md) | [(2.02)](/filings/0001193125-26-092567.md) | [(3.18)](/filings/0001193125-26-092567.md) | | Free cash flow | $m | [(106)](/filings/0000950170-24-021094.md) | [(111)](/filings/0000950170-25-029975.md) | [(125)](/filings/0001193125-26-092567.md) | [134](/filings/0001193125-26-092567.md) | [(70.7)](/filings/0001193125-26-092567.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/kura/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $115.3m | 10,509,233 | | Added +871,702 | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $94.1m | 8,575,422 | | Unchanged | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $92.7m | 8,445,769 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $58.5m | 5,329,208 | | Added +817,317 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $43.0m | 3,916,164 | | Added +130,479 | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $40.3m | 3,678,000 | | Reduced −58,000 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $34.3m | 3,126,727 | | Added +1,002,247 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $24.8m | 2,265,171 | | Added +831,700 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $24.5m | 2,229,958 | | Added +195,682 | | [ALETHEA CAPITAL MANAGEMENT, LLC](/funds/1549408.md) | 2026-06-30 | $23.8m | 2,167,938 | | Added +638,569 | ## Recent filings [All 789 filings](/companies/kura/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-09 | 07:05 ET | [8-K](/filings/0001193125-26-385881.md) | 8.01 Other events | 0001193125-26-385881 | | 2026-09-08 | 07:05 ET | [8-K](/filings/0001193125-26-384363.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-384363 | | 2026-08-12 | 16:15 ET | [10-Q](/filings/0001193125-26-346884.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346884 | | 2026-08-12 | 16:10 ET | [8-K](/filings/0001193125-26-346856.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346856 | | 2026-07-29 | 17:06 ET | [8-K](/filings/0001193125-26-324202.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-324202 | | 2026-06-04 | 16:05 ET | [8-K](/filings/0001193125-26-257368.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-257368 | | 2026-05-12 | 16:15 ET | [10-Q](/filings/0001193125-26-219481.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219481 | | 2026-05-12 | 16:10 ET | [8-K](/filings/0001193125-26-219422.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219422 | | 2026-04-10 | 16:25 ET | [DEF 14A](/filings/0001193125-26-151335.md) | Proxy statement, period 2026-06-04 | 0001193125-26-151335 | | 2026-03-05 | 07:31 ET | [10-K](/filings/0001193125-26-092567.md) | Annual report, period 2025-12-31 | 0001193125-26-092567 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-092567.md), filed Mar 5, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8aa6bf95-62ce-4ebf-8b79-f7f5b5cc2dcf) ## About the filer - CIK: 1422143 - Tickers: KURA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.